DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway

Liu, Shi-lei; Cai, Chen; Yang, Zi-yi; Wu, Zi-you; Wu, Xiang-song; Wang, Xue-feng; Dong, Ping; Gong, Wei

doi:10.7150/ijbs.55636



Theranostics

International Journal of Medical Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Biol Sci 2021; 17(2):498-513. doi:10.7150/ijbs.55636 This issue Cite

Research Paper

DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway

Shi-lei Liu^1,2*, Chen Cai^1,2*, Zi-yi Yang^1,2*, Zi-you Wu¹, Xiang-song Wu^1,2, Xue-feng Wang^1,2, Ping Dong^1,2✉, Wei Gong^1,2✉

1. Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China
2. Shanghai Key Laboratory of Biliary Tract Disease Research, No. 1665 Kongjiang Road, Shanghai 200092, China
*These authors contributed equally to this work.

Citation:

Liu Sl, Cai C, Yang Zy, Wu Zy, Wu Xs, Wang Xf, Dong P, Gong W. DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Int J Biol Sci 2021; 17(2):498-513. doi:10.7150/ijbs.55636. https://www.ijbs.com/v17p0498.htm

Other styles

Abstract

Long noncoding RNA DiGeorge syndrome critical region gene 5 (DGCR5) has been shown to be highly associated with cancer development. However, the biological role and molecular mechanism of DGCR5 in pancreatic cancer (PC) remains largely unknown. This study aimed to explore the role of DGCR5 in PC. It was revealed that DGCR5 was highly expressed in PC tissues compared with adjacent normal tissues and was associated with poor prognosis in PC patients. Furthermore, DGCR5 depletion inhibited the proliferation, migration and invasion by increasing apoptosis and inducing G0/G1 cell cycle arrest in vitro. Moreover, xenograft assay validated that DGCR5 promotes PC tumor growth in vivo. Mechanistically, DGCR5 was found to act as a ceRNA by sponging miR-3163 to regulate DNA topoisomerase 2-alpha (TOP2A) and inhibit Wnt/β-catenin pathway. In addition, it was found that DGCR5 downregulation could enhance the sensitivity of PC cells to gemcitabine, and ChIP assay showed that PAX5 (Paired Box 5) could bind to the promoter region of DGCR5 and increase its transcription. The results of the present study indicated that DGCR5 may be a potential diagnostic biomarker and therapeutic target for PC.

Keywords: DGCR5, PAX5, miR-3163, TOP2A, Wnt/β-catenin pathway, pancreatic cancer

Citation styles

APA

Liu, S.l., Cai, C., Yang, Z.y., Wu, Z.y., Wu, X.s., Wang, X.f., Dong, P., Gong, W. (2021). DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. International Journal of Biological Sciences, 17(2), 498-513. https://doi.org/10.7150/ijbs.55636.

ACS

Liu, S.l.; Cai, C.; Yang, Z.y.; Wu, Z.y.; Wu, X.s.; Wang, X.f.; Dong, P.; Gong, W. DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Int. J. Biol. Sci. 2021, 17 (2), 498-513. DOI: 10.7150/ijbs.55636.

NLM

CSE

Liu Sl, Cai C, Yang Zy, Wu Zy, Wu Xs, Wang Xf, Dong P, Gong W. 2021. DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Int J Biol Sci. 17(2):498-513.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.